- Wanhua Chemical’s polyurethanes series revenue stood at 75.84 billion yuan, surpassing the expected 71.39 billion yuan.
- The petrochemical series revenue was 72.52 billion yuan, falling short of the projected 78.97 billion yuan.
- Revenue from the fine chemicals and new materials series reached 28.27 billion yuan, exceeding the estimate of 27.49 billion yuan.
- The final dividend per share was declared at 73 RMB cents, which is lower than the expected 1.44 yuan.
- For the first quarter, Wanhua Chemical reported a net income of 3.08 billion yuan and total revenue of 43.07 billion yuan.
- Earnings per share (EPS) for the first quarter were recorded at 98 RMB cents.
- Analyst recommendations include 26 buys, 1 hold, and 2 sells for Wanhua Chemical.
A look at Wanhua Chemical Group Co A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Wanhua Chemical Group Co A has received a promising outlook. With a high Dividend score of 5 and strong Momentum score of 5, the company is seen favorably in terms of its ability to provide returns to investors and its current upward trend in performance. Additionally, the company scores moderately in areas of Value, Growth, and Resilience with scores of 3, indicating a stable foundation for potential long-term growth.
Wanhua Chemical Group Co A, known for developing, manufacturing, and marketing chemical products such as pure isocyanate and polyurethane, demonstrates a well-rounded position in the market. With a favorable dividend outlook and positive momentum, coupled with a solid foundation in key areas, the company appears poised for sustained success in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
